AU2016248443B2 - Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone - Google Patents

Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone Download PDF

Info

Publication number
AU2016248443B2
AU2016248443B2 AU2016248443A AU2016248443A AU2016248443B2 AU 2016248443 B2 AU2016248443 B2 AU 2016248443B2 AU 2016248443 A AU2016248443 A AU 2016248443A AU 2016248443 A AU2016248443 A AU 2016248443A AU 2016248443 B2 AU2016248443 B2 AU 2016248443B2
Authority
AU
Australia
Prior art keywords
conditions
fmd
rapamycin
dexamethasone
standard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016248443A
Other languages
English (en)
Other versions
AU2016248443A1 (en
Inventor
Stefano DI BIASE
Valter D. Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2016248443A1 publication Critical patent/AU2016248443A1/en
Application granted granted Critical
Publication of AU2016248443B2 publication Critical patent/AU2016248443B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2016248443A 2015-04-16 2016-04-18 Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone Active AU2016248443B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (2)

Publication Number Publication Date
AU2016248443A1 AU2016248443A1 (en) 2017-11-02
AU2016248443B2 true AU2016248443B2 (en) 2021-03-18

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016248443A Active AU2016248443B2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Country Status (14)

Country Link
US (2) US20160303056A1 (https=)
EP (2) EP3283073A4 (https=)
JP (2) JP2018511625A (https=)
KR (1) KR20180002677A (https=)
CN (1) CN107613979A (https=)
AU (1) AU2016248443B2 (https=)
BR (1) BR112017022244A2 (https=)
CA (2) CA2982875C (https=)
HK (1) HK1249858A1 (https=)
IL (1) IL255026A0 (https=)
MX (1) MX2017013133A (https=)
RU (1) RU2734774C2 (https=)
WO (1) WO2016168802A2 (https=)
ZA (1) ZA201707710B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023748A2 (pt) 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
KR20180120153A (ko) 2016-02-15 2018-11-05 유니버시티 오브 써던 캘리포니아 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CA3134756A1 (en) 2019-04-30 2020-11-05 Valter D. Longo Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
EP4164407A4 (en) * 2020-06-14 2024-08-28 L-Nutra Inc. BAR/DRINK FOR INTERMITTENT FASTING THAT MAINTAINS AND PROLONGS THE FASTING STATE
EP4180047A4 (de) * 2020-07-10 2024-03-13 Martynova, Elena Anatol'evna Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779282C (en) * 2009-10-22 2017-12-05 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
CN103347521B (zh) * 2010-12-06 2018-05-25 全球癌症治疗有限责任公司 用于治疗癌症的使用化疗和免疫治疗的代谢靶向癌细胞的方法
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
US9386790B2 (en) * 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ERIC C. WOOLF ET AL, "The ketogenic diet for the treatment of malignant glioma", JOURNAL OF LIPID RESEARCH, US, (2014-02-06), vol. 56, no. 1, doi:10.1194/jlr.R046797, ISSN 0022-2275, pages 5 - 10 *

Also Published As

Publication number Publication date
RU2734774C2 (ru) 2020-10-23
CN107613979A (zh) 2018-01-19
KR20180002677A (ko) 2018-01-08
WO2016168802A2 (en) 2016-10-20
CA3108664A1 (en) 2016-10-20
EP3283073A2 (en) 2018-02-21
RU2017136423A3 (https=) 2019-09-04
JP2018511625A (ja) 2018-04-26
ZA201707710B (en) 2019-04-24
EP4299061A2 (en) 2024-01-03
CA2982875C (en) 2021-10-19
JP2021008491A (ja) 2021-01-28
EP4299061A3 (en) 2024-02-28
HK1249858A1 (zh) 2018-11-16
EP3283073A4 (en) 2019-02-13
IL255026A0 (en) 2017-12-31
BR112017022244A2 (pt) 2018-07-10
US20210137856A1 (en) 2021-05-13
US20160303056A1 (en) 2016-10-20
MX2017013133A (es) 2018-09-07
AU2016248443A1 (en) 2017-11-02
RU2017136423A (ru) 2019-05-16
CA2982875A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
AU2016248443B2 (en) Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
EP3297037A4 (en) Preparation method for solar cell piece unit and solar cell module
EP3084830A4 (en) Liner for phase change memory (pcm) array and associated techniques and configurations
EP2923248A4 (en) Reversible folio for tablet computer with reversible connection for keyboard and reading configuration
EP3238070A4 (en) Memory protection with non-readable pages
EP3019936A4 (en) Fast multi-touch post processing
EP3073522A4 (en) Array substrate and preparation method therefor, and display device
EP3227932A4 (en) Barrier film techniques and configurations for phase-change memory elements
EP3088951A4 (en) Array substrate, preparation method thereof, motherboard comprising array substrate and display apparatus
EP3069171A4 (en) Seismic data processing
EP3149607A4 (en) Fast access rights checking of configured structure data
EP3259868A4 (en) Protecting sensitive data security
EP3279949A4 (en) Solar cell module
EP3260456A4 (en) Heterocyclic compound and organic solar cell comprising same
EP3041476A4 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP3298918A4 (en) Improvements to skull protection cell
EP3066496B8 (en) Device and method for detecting neutrons and gamma rays
EP3287443A4 (en) 6-membered heterocyclic derivative and pharmaceutical composition comprising same
EP3014670A4 (en) Transparent conductive coatings for organic photovoltaic films
EP3241116A4 (en) Memory access protection using processor transactional memory support
EP3064500A4 (en) Single molecule and organic solar cell comprising same
EP3140673A4 (en) Gamma detector protection for downhole operations
EP3389098A4 (en) Solar cell module
EP3208654A4 (en) Short-circuit unit and array substrate
EP3276695A4 (en) Organic thin film solar cell module

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)